What Is Regenerative Medicine?
Regenerative Medicine is the use of one’s own cells to help promote healing and decrease pain. The procedure allows the body’s own mechanism to release growth factors to improve range of motion and quality of life.
Who Is A Candidate For This Procedure?
The ideal recipient is one that wants their body’s own potential as an option to possibly delay and or prevent surgery.
What Are The Ideal Joints To Inject?
- Problems of the knee including osteoarthritis, meniscal tears, bursitis.
- Problems of the hip including osteoarthritis, labral tears, bursitis.
- Problems of the shoulder including osteoarthritis, partial rotator cuff tears, bursitis.
In the procedure, the physician will aspirate adipose (fatty) tissue. Because your own cells are used, the procedure is considered to be “autologous point-of-care.” Platelet-rich plasma is obtained from your blood. The combination of these two are injected into the painful joint.
What Can I Expect From the Treatment?
The procedure is performed in the medical office. Most cases of stem cells and PRP treatments are successful, and avoid the pain, inability, down time, and risk associated with major surgery. There is
minimal recovery from the procedure. Patients return to work the following day.
There are no sutures required.
When Can I Resume Physical Activity?
The most important part of any regenerative medicine therapy procedure is adhering to your post-procedure restrictions. For this procedure to have the best chance to yield lasting benefits one must:
• Avoid anti-inflammatory medications for two weeks post-procedure
• Rest as much as possible for the first 24 – 48 hours
• Restrict activity to general walking only for 2 – 3 weeks
• After 4 weeks, weightlifting and running are permitted.
A. Disease Background
1) Brooks P. The burden of musculoskeletal disease – a global perspective. Clin Rheumatol. 2006; 25:778-781.
2) Longo, Fauci, Kasper, Hauser, Jameson, Loscanzo, editors. Harrison’s Principles of Internal Medicine, 18th Edition. New York: McGraw Hill Medical, 2012 pp.2828-2836.
3) Sarzi-Putini P, et al. Osteoarthritis: An overview of the disease and it treatment strategies. Semin Arthritis Rheum. 2005; 35:1-10
B. Autologous Adipose-Derived Stromal Cells (ASCs)
1) Chen FH, Tuan RS Mesenchymal stem cells in arthritic disease. Arthritis Res and Ther. 2008; 10:223-236
2) Carstairs A, Genever P. stem cell treatment for musculoskeletal disease. Current Opinion in Pharmacology. 2014, 16: 1-6
3) Lacitignola L, et.al. Cell therapy for tendonitis, experimental and clinical report. Vet Res Commun. 2008; Sup: 32 suppl 1: S 33-8.
4) Renzi S, et al. Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligament and tendons: a clinical report. Res Vet Sci. 2013 Aug 95(1):272-7.
5) Centeno CJ, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal cells. Pain Physician 2008: 11(3):343-353.
6) Emadedin M, et al. Intra-articular injection of autologous mesenchymal cells in six patients with knee osteoarthritis. Anthroscopy 2013: 29(4): 748-55.
7) Koh YG, et al. Mesenchymal stem cell injections improve symptoms of knee osteoarthriti. Arch Iraanian Med. 2012:15(7):422-428.
8) J o CH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof of concept clinical trial. Stem Cells 2013: DOI: 10.1002/stem.1634.
C. Fat Harvesting References
1) Fournier, PF. Reduction syringe lipo contouring. Dermatol Clin, 1990; 8:539.
2) Hunsted, JP. Tumescent and syringe liposculture: a logical partnership. Aesth Plast Surg. 1995; 19:321-333.
3) Klein J. Tumescent technique chronicles. Dermatol Surg. 1995: 21:449-457.
4) Housman TS, et al. The safety of liposuction: results of national survey. Dermatol Surg. 2002; 08:971-978.
5) Tierney EP, Kouba DJ, Hanke CW. Safety of tumescent and laser-assisted liposuction: Review of the literature. J Drugs Dermatol. 2011 Dec; 10(12):1363-1369.
6) Boeni, R. Safety of tumescent liposuction under local anesthesia in a series of 4380 patients. Dermatology. 2011; 222(3): 278-81.
7) Habbema, L. Safety of liposuction using exclusively tumescent local anesthesia in 3420 consecutive cases. Dermatol Sur. 2009 Nov;35(11): 1728-1735.
8) Leong DT, et al. Viability and adipogenic potential of human adipose tissue processed cell population obtained from pump-assisted and syringe-assisted liposuction. J. Dermatol Sci. 2005: 37: 169-176.
9) Cheriyan T, et al. Low harvest pressure enhances autologous fat graft viability. Plast Reconstr Surg. 2014
June; 133(6): 1365-1368.
10) Rohrjch RJ, et al. Fat Grafting: evidence- based review on autologous fat harvesting, processing, reinjection, and storage. Plast Reconstr Surg 2012; 30(1): 249-258.
11) Alharbi Z. et al. Conventional vs. micro-fat harvesting: how fat harvesting technique aǺects tissue-engineering approaches using adipose tissue-derived stem/stromal cells. J Plast Reconstr Aesth Surg. 2013; 66 1271-1278.
D. Cell Processing References
1) Rodbell M. Jones AB. Metabolism of isolated fat cells 3. The similar inhibitory action of phospholipase C (clostridium perfringens alpha toxins) and insulin on lipolysis stimulated by lipolytic hormones and theophylline. J. Biol Chem. 1966; 241: 140-142
2) Bunell BA, et al. Adipose-derived stem cells; isolation, expansion and differentiation. Methods. 2008; 45: 115- 120.
3) Baptista. L, et al. Processing of lipoaspirate samples for optimal mesenchymal stem cells isolation. Advanced Techniques in Liposuction and fat Transfer chapter. www.intechopen.com
E. Platelet Rich Plasma
1) Bielecki TM, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances. J Bone Joint Surg BR. 2007-89-B: 417-20.
2) Chen L, et al. Antibacterial eǺect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro. J Diabetes Res 2013:doi. org/10.1155/2013/269527
3) Burnouf et al. Antimicrobial activity of platelet (PTLpoor Transfusion. 2013; 531(1):138-46 PLT lysate biomaterials against wound bacteria. Transfusion, 2013; 53(1) 138-46.
4) Yang Y. et al Antibacterial effect of autologous platelet-rich gel derived from health volunteers in vitro. Zhonggus Xiu Fu Chong Jian Waike Za Zhi. 2010;24(5):571-6.
F. Diagnostic Assessment
1) McConnells, et al. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); a review of its utility and measurement properties. Arthritis Rheum 2001; 45(5):453-461.
2) Raman J. Macdermid JC, Western Ontario Rotator Cu Index. Journal of Physiotherapy. 2012:58:102.
3) Meenan RF, German PM Mason JH. Measuring Health status in arthritis: the Arthritis Impact Measurement Scale. Arthritis Rheumatism 1980:23:146-52.
4) Ren XS, Kazis L. Meenan RF. Short-form Arthritis Impact Measurement Scale 2: tests of reliability and validity among patients with osteoarthritis. Arthritis care Res. 1999; 12(3): 163-71.
Disclaimer: Clinical studies have shown marked improvement in patients treated. All patients are enrolled in investigative research board clinical studies with specific protocols. This procedure is not FDA approved. Insurance companies do not pay for this procedure.
FDA Disclosure: Healthy Aging Medical Centers and its affiliate treatment centers are not offering stem cell therapy as a cure for any condition, disease, or injury. No statements or implied treatments in this brochure have been evaluated or approved by the FDA. This brochure contains no medical advice. All statements and opinions provided by this brochure are provided for educational and informational purposes only and we do not diagnose or treat via this brochure or via telephone. Healthy Aging Medical Centers and its affiliate treatment centers are offering patient funded research to provide individual patients with Stromal Vascular Fraction that contains their own autologous stem cells and growth factors and the treatment centers provide surgical procedures only and are not involved in the use or manufacture of any investigational drugs. Healthy Aging Medical Centers network does not claim that any applications, or potential applications, using autologous stem cells are approved by the FDA, or are even effective. We do not claim that these treatments work for any listed nor unlisted condition, intended or implied. It’s important for potential patients to do their own research based on the options that we present so that one can make an informed decision. Any decision to participate in our patient funded experimental protocols is completely voluntary.
ATTENTION: If you have ANY concern with stromal vascular fraction, any of our products, methods, website, brochure or technique and think we may be violating any U.S. law, please contact us so that we can investigate the matter or concern immediately.